Edgewise Therapeutics

What Edgewise Therapeutics does

Edgewise Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado, developing small-molecule therapeutics for serious muscle diseases. The company operates a proprietary muscle-focused drug discovery platform that combines foundational expertise in muscle biology with medicinal chemistry to target both skeletal and cardiac muscle. Its clinical pipeline has historically comprised sevasemten (EDG-5506), an orally administered first-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies; EDG-7500, a selective cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM); EDG-15400, a cardiac sarcomere modulator for heart failure with preserved ejection fraction (HFpEF); and the preclinical EDG-003 cardiometabolic program. The company is publicly traded on NASDAQ under the ticker EWTX following a 2021 IPO, employs 101–250 staff, and has raised over $440M across post-IPO equity offerings in 2024 and 2025.

The company's competitive positioning rests on mechanism differentiation: sevasemten is the only oral fast skeletal myosin inhibitor in late-stage development for muscular dystrophy and has shown sustained functional stabilization through 3.5 years in the MESA open-label extension, while EDG-7500 demonstrated no meaningful reductions in left ventricular ejection fraction in CIRRUS-HCM Phase 2 — differentiating it from existing cardiac myosin inhibitors Camzyos and Myqorzo that require REMS-style echocardiographic monitoring. End customers are patients with serious, progressive muscle diseases served through specialty cardiology and neuromuscular channels; the company does not yet have approved products and therefore has no commercial revenue.

Edgewise's business model is pre-commercial R&D funded by equity capital and collaboration proceeds. In June 2026, the company announced the sale of its muscular dystrophy business, including sevasemten, to Servier for up to $2.65 billion ($1.55B upfront plus up to $1.1B in milestones), pivoting the company to a cardiovascular-focused strategy while retaining rights to EDG-7500, EDG-15400, and EDG-003. Following the deal, the company plans to advance EDG-7500 into Phase 3 in Q4 2026 and has begun commercial-readiness staffing, including a board appointment of Verona Pharma's former CCO (Christopher Martin) to support U.S. launch. As of Q1 2026, Edgewise reported a net loss of $49.0M and a cash position of approximately $499.6M, supplemented by the pending Servier proceeds expected to close in Q3 2026.

Name

Edgewise Therapeutics

Legal name

Edgewise Therapeutics, Inc.

Website

https://edgewisetx.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious muscle diseases, with a pipeline centered on EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for HFpEF following the 2026 Servier divestiture of its muscular dystrophy business.

Ownership category

akta.pro rank

Product category

Cardiovascular and Musculoskeletal Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Muscular dystrophy therapeutics
• Cardiac sarcomere modulators
• Small molecule drug discovery
• Hypertrophic cardiomyopathy treatment
• Rare disease biopharmaceuticals

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-commercial Drug Development: Edgewise Therapeutics is a clinical-stage biopharmaceutical company with no current commercialized products. The company is developing therapeutics for muscular dystrophies and serious cardiac conditions. Following the sale of its muscular dystrophy business to Servier for up to $2.65 billion, the company plans to focus on its cardiovascular pipeline. The company reported a Q1 2026 net loss of $49.0 million with R&D expenses of $42.7 million. Cash position was approximately $499.6 million as of March 31, 2026.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing proprietary small molecule therapeutics for serious muscle diseases. Its pipeline includes sevasemten (first-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, sold to Servier in 2026), EDG-7500 (selective cardiac sarcomere modulator for hypertrophic cardiomyopathy), EDG-15400 (cardiac sarcomere modulator for HFpEF), and preclinical EDG-003 for cardiometabolic indications. The company has no commercialized products and conducts business through clinical development and strategic licensing/divestiture transactions.

Product overview

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for serious muscle diseases. The company's product portfolio consists of four drug candidates: Sevasemten (EDG-5506), an orally administered first-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies; EDG-7500, a selective cardiac sarcomere modulator for hypertrophic cardiomyopathy; EDG-15400, a cardiac sarcomere modulator for heart failure with preserved ejection fraction (HFpEF); and EDG-003, a preclinical cardiometabolic program. Following the sale of its muscular dystrophy business to Servier in 2026, the company is pivoting to become a cardiovascular-focused company while retaining rights to its cardiovascular pipeline including EDG-7500 and EDG-15400.

Differentiator

Problem solved

Functional benefit

Brands

• Sevasemten: An orally administered first-in-class fast skeletal myosin inhibitor for muscular dystrophies including Becker and Duchenne. Previously part of Edgewise's pipeline, now sold to Servier.
• EDG-7500
• EDG-15400

Products and services

• Sevasemten (EDG-5506) An orally administered first-in-class fast skeletal myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced damage in Becker and Duchenne muscular dystrophies. Targets contraction-induced muscle damage, the root cause of progressive muscle breakdown. Sold to Servier in June 2026 for up to $2.65 billion.
• EDG-7500 A novel oral, selective cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy (HCM), designed to slow early contraction velocity and address impaired cardiac relaxation. In Phase 2, 90% of obstructive HCM patients demonstrated hemodynamic improvement and 74% achieved NT-proBNP normalization, with no meaningful reduction in left ventricular ejection fraction.
• EDG-15400 A novel oral, selective cardiac sarcomere modulator for the treatment of heart failure with preserved ejection fraction (HFpEF) and other diseases of cardiac diastolic dysfunction.
• EDG-003 A preclinical-stage cardiometabolic program featuring an undisclosed cardiac sarcomeric agent for cardiometabolic indications.

Quantifiable outcome

• 90% of obstructive HCM patients demonstrated improvement in hemodynamic measures with EDG-7500
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• ServiercoreStrategic or Co-development Partner · 1 June 2026Servier entered into a definitive agreement to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, comprising a $1.55 billion upfront payment and up to $1.1 billion in regulatory and commercial milestones. The acquisition includes sevasemten, an investigational first-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, currently in pivotal trials for BMD and Phase 2 for DMD. The transaction was unanimously approved by both companies' boards and is expected to close in Q3 2026 pending regulatory approvals.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cytokinetics: Clinical-stage biopharmaceutical company developing cardiac sarcomere modulators including aficamten (HCM) and CK-586 (HFpEF). Direct competitor in cardiac sarcomere modulation, targeting the same HCM market as Edgewise with EDG-7500.

Broad incumbents

• Bristol-Myers Squibb: Acquired MyoKardia and markets Camzyos (mavacamten), the first FDA-approved cardiac myosin inhibitor for HCM. Sets the competitive benchmark for EDG-7500 and is the dominant incumbent in the obstructive HCM space.
• BridgeBio Pharma: Through its acquisition of MyoKardia and ongoing cardiovascular programs (including aficamten successor assets), BridgeBio is a broad incumbent in HCM and cardiac disease with overlapping cardiovascular R&D and physician relationships.
• Pfizer: Markets Myqorzo (acquired through the 2025 Arena/Cardiff transaction), a second cardiac myosin inhibitor advancing in HCM. Competes with EDG-7500 for HCM share and represents a large-pharma commercialization benchmark.
• Sarepta Therapeutics: Commercial leader in Duchenne muscular dystrophy therapies. While Edgewise has divested its MD business, Sarepta provides relevant comparability for the muscular dystrophy segment that was just sold to Servier and the historical muscle-disease platform.
• BioMarin Pharmaceutical: Develops and markets therapies for rare diseases including Duchenne muscular dystrophy. Comparable to Edgewise's pre-divestiture muscular dystrophy franchise (now sold to Servier) and to rare-disease commercial strategy.

Emerging players

• Tenaya Therapeutics: Clinical-stage gene therapy company focused on genetic cardiomyopathies including HCM. Targets overlapping patient populations as EDG-7500 via a different modality (gene therapy vs. small molecule), representing a forward-looking competitive threat.
• Lexeo Therapeutics: Clinical-stage gene therapy company with cardiac disease programs including HCM and other inherited cardiomyopathies. Adjacent competitor exploring alternative modalities for the same cardiovascular indications.
• Capricor Therapeutics: Clinical-stage biotech developing cell therapy and exosome-based treatments for Duchenne muscular dystrophy and cardiac indications. Overlaps with Edgewise's historical muscle and cardiac programs.
• Solid Biosciences: Clinical-stage gene therapy company targeting Duchenne muscular dystrophy and other neuromuscular diseases. Comparable to Edgewise's former muscular dystrophy pipeline that underpinned the Servier deal.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/EdgewiseTx
• YouTubeyoutube.com/@EdgewiseTherapeutics/featured
• Facebookfacebook.com/Edgewisetx
• LinkedInlinkedin.com/company/edgewisetx
• Instagraminstagram.com/edgewisetherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds6 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edgewise Therapeutics